References
- Ebbehoj A, Stochholm K, Jacobsen SF, Trolle C, Jepsen P, Robaczyk MG, et al. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. Journal of Clinical Endocrinology and Metabolism. 2021;106(5): e2251-e2261.
- Ebbehoj A, Li D, Kaur RJ, Zhang C, Singh S, Li T, et al. Epidemiology of Adrenal Tumors - a Population-based Study in Olmsted County, Minnesota. Lancet Diabetes Endocrinol. 2020;8(11): 894-902.
- Beninato T, Kluijfhout WP, Drake FT, Lim J, Kwon JS, Xiong M, et al. Resection of Pheochromocytoma Improves Diabetes Mellitus in the Majority of Patients. Ann Surg Oncol. 2017;24(5): 1208-1213.
- Elenkova A, Matrozova J, Vasilev V, Robeva R, Zacharieva S. Prevalence and progression of carbohydrate disorders in patients with pheochromocytoma/paraganglioma: retrospective single-center study. Ann Endocrinol (Paris). 2020;81(1): 3-10.
- Liu ZH, Zhou L, Lin L De, Chen T, Jiang QY, Liu ZH, et al. Will the resection of pheochromocytoma improve preoperative diabetes mellitus? Asian J Surg. 2019;42(12): 990-994.
- Moustaki M, Paschou SA, Vakali E, Xekouki P, Ntali G, Kassi E, et al. Secondary diabetes mellitus in pheochromocytomas and paragangliomas. Endocrine. 2023; 82(3): 467-479.
- Kleihues P, Sobin LH. World Health Organization Classification of Tumors. Cancer. 2000;88(12): 2887.
- DeLellis RA, Lloyd RV, Heitz PU (eds.). Pathology and Genetics of Tumors of Endocrine Organs, International Agency for Research on Cancer (IARC Press), Lyon.2004; 57–66.
- Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds.). Pathology and Genetics of Tumors of Endocrine Organs, International Agency for Research on Cancer (IARC Press), Lyon.2017; 180-207.
- Thompson LDR. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. American Journal of Surgical Pathology. 2002;26(5): 551-66.
- Lopez C, Bima C, Bollati M, Bioletto F, Procopio M, Arata S, et al. Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma. Vol. 24, International Journal of Molecular Sciences. 2023;24(6): 5153.
- Ioakim KJ, Sydney GI, Paschou SA. Glucose metabolism disorders in patients with adrenal gland disorders: pathophysiology and management. Hormones. 2020;19(2):135-143.
- Abe I, Fujii H, Ohishi H, Sugimoto K, Minezaki M, Nakagawa M, et al. Differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma. Endocr J. 2019;66(2): 187-192.
- Ronen JA, Gavin M, Ruppert MD, Peiris AN. Glycemic Disturbances in Pheochromocytoma and Paraganglioma. Cureus. 2019;11(4):e4551.
- Zhao L, Zhang T, Meng X, Zhang Z, Zhou Y, Fan H, et al. Factors contributing to development and resolution of dysglycemia in patients with pheochromocytomas and catecholamine-secreting paragangliomas. Ann Med. 2023;55(1): 2203945.
- Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(8): 1443-1456.
- Colwell JA. Inhibition of insulin secretion by catecholamines in pheochromocytoma. Ann Intern Med. 1969;71(2): 251-6.
- Stenstrom G, Sjostrom L, Smith U. Diabetes mellitus in phaeochromocytoma. Fasting blood glucose levels before and after surgery in 60 patients with phaeochromocytoma. Acta Endocrinol (Copenh). 1984; 106(4): 511-5.
- La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens. 2003;21(9): 1703-7.
- Pogorzelski R, Toutounchi S, Krajewska E, Fiszer P, Łykowski M, Zapała Ł, et al. The effect of surgical treatment of phaeochromocytoma on concomitant arterial hypertension and diabetes mellitus in a single-centre retrospective study. Cent European J Urol. 2014;67(4): 361-5.